"Rocky Mountain Cancer Centers (RMCC) is Colorado's largest and most comprehensive provider of cancer care with over 50 physicians, in nearly 20 community-based locations across the state. Our history is rich in forward thinking and best practice development. We were formed in 1992 when a group of independent medical oncology practices joined together to become a network of community-based clinic sites. This practice model has stood the test of time and continues to have proven clinical and economic benefit for patients, employers and payers today."

During the past decade, Rocky Mountain Cancer Centers-Penrose conducted 157 clinical trials. In the 10-year time frame, 157 clinical trials started and 76 clinical trials were completed, i.e. on average, 48.4% percent of trials that started reached the finish line to date. In the past 5 years, 67 clinical trials started and 62 clinical trials were completed. i.e. 92.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rocky Mountain Cancer Centers-Penrose" #1 sponsor was "National Cancer Institute (NCI)" with 94 trials, followed by "SWOG Cancer Research Network" with 36 trials sponsored, "Alliance for Clinical Trials in Oncology" with 24 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 17 trials sponsored and "Pfizer" with 17 trials sponsored. Other sponsors include 33 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rocky Mountain Cancer Centers-Penrose" #1 collaborator was "National Cancer Institute (NCI)" with 96 trials as a collaborator, "NRG Oncology" with 22 trials as a collaborator, "Canadian Cancer Trials Group" with 6 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator and "Genentech, Inc." with 2 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Rocky Mountain Cancer Centers-Penrose" are "Recurrent Squamous Cell Lung Carcinoma" (10 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials), "Recurrent Ovarian Carcinoma" (7 trials), "Stage IV Lung Cancer AJCC v8" (7 trials) and "Invasive Breast Carcinoma" (6 trials). Many other conditions were trialed in "Rocky Mountain Cancer Centers-Penrose" in a lesser frequency.

Most popular intervention types in "Rocky Mountain Cancer Centers-Penrose" are "Drug" (175 trials), "Other" (118 trials), "Biological" (92 trials), "Procedure" (52 trials) and "Radiation" (28 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (56 trials), "Quality-of-Life Assessment" (48 trials), "Computed Tomography" (31 trials), "Questionnaire Administration" (29 trials) and "Nivolumab" (28 trials). Other intervention names were less common.

The vast majority of trials in "Rocky Mountain Cancer Centers-Penrose" are 177 trials for "All" genders, 32 trials for "Female" genders and 8 trials for "Male" genders.

Currently, there are NaN active trials in "Rocky Mountain Cancer Centers-Penrose". undefined are not yet recruiting, 62 are recruiting, 98 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 44 completed trials in Rocky Mountain Cancer Centers-Penrose, 3 suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Rocky Mountain Cancer Centers-Penrose, 5 "Phase 1" clinical trials were conducted, 107 "Phase 2" clinical trials and 109 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".